Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials

The combination of EGFR inhibitors and anti-angiogenic drugs has a strong pre-clinical rationale, yet its use has produced controversial clinical results. We conducted two sequential phase I trials to evaluate the feasibility and the recommended dose of erlotinib when combined with fluoropyrimidine-...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: CARLOMAGNO, CHIARA, DANIELE, GENNARO, BIANCO, ROBERTO, MARCIANO, ROBERTA, DAMIANO, VINCENZO, MATANO, ELIDE, NAPPI, LUCIA, PEPE, STEFANO, DE PLACIDO, SABINO, TORTORA, GIAMPAOLO
Формат: Artigo
Язык:Inglês
Опубликовано: D.A. Spandidos 2011
Предметы:
Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3440709/
https://ncbi.nlm.nih.gov/pubmed/22977524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/etm.2011.218
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы